Rising prices for the most common drugs in the United States could trigger a wave, as the costs of some of the most important drugs in patients’ lives continue to rise.
The number of generic medicines in the country is expected to surpass 100 million in 2019, a number that could rise further in the coming years.
The pharmaceutical industry is not expecting the drug prices to fall dramatically in the near future, though.
“We expect to see the number of generics in the U.S. grow as a result of continued price pressures,” said Dan Gertz, a spokesman for the Association of American Pharmaceutical Industries.
The growth of generic drugs is part of a broader shift in the way drugs are manufactured and sold.
In recent years, drugmakers have been trying to cut costs by turning to cheaper, more generic versions of older drugs.
But as companies like Pfizer and Johnson & Johnson continue to make blockbuster drugs, they’re also facing new competition from cheaper and more generic alternatives.
For instance, in 2014, drugmaker Novartis stopped selling an older version of an antibiotic called cefixime and turned to cheaper versions of it.
Now, Novartists is selling a generic version of cefazolin, which is used to treat urinary tract infections.
And in the first quarter of 2019, Johnson &s; Johnson said it was switching from a generics to a cheaper version of its antibiotic-resistance drug, Oxidase-3.